Last reviewed · How we verify
Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
Details
| Lead sponsor | QuatRx Pharmaceuticals Company |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2006-02 |
| Completion | 2007-10 |
Conditions
- Hypogonadism
Interventions
- Fispemifene once daily for 4 weeks
Primary outcomes
- Change in morning total testosterone levels from baseline to Week 4 (end of therapy)
Countries
United States